mhurhangee/ep-ind-claims huggingface dataset:
A method for transmitting a synchronization signal block, SSB, on an unlicensed spectrum, comprising: determining, by a network device, that a first transmission opportunity, TXOP, on an unlicensed carrier includes K SSB positions capable of being used to transmit SSBs, where K is less than a number X of SSBs configured by the network device for transmission on the unlicensed carrier, and K and X are both positive integers; and respectively transmitting, by the network device, K SSBs of the X SSBs at the corresponding K SSB positions within the first TXOP, wherein the method further comprises: transmitting, by the network device, remaining X-K SSBs of the X SSBs within a second TXOP after the first TXOP, wherein each of the X SSBs is transmitted at a candidate SSB position corresponding to the SSB, and different SSBs correspond to different candidate SSB positions, wherein transmitting, by the network device, the remaining X-K SSBs of the X SSBs within the second TXOP after the first TXOP comprises: transmitting, by the network device, an SSB from a first SSB position capable of being used to transmit SSB within the second TXOP until the remaining X-K SSBs are transmitted, characterized in that, the network device repeatedly transmits the K SSBs respectively at K SSB positions corresponding to the K SSBs within the second TXOP. determining, by a network device, that a first transmission opportunity, TXOP, on an unlicensed carrier includes K SSB positions capable of being used to transmit SSBs, where K is less than a number X of SSBs configured by the network device for transmission on the unlicensed carrier, and K and X are both positive integers; and respectively transmitting, by the network device, K SSBs of the X SSBs at the corresponding K SSB positions within the first TXOP, wherein the method further comprises: transmitting, by the network device, remaining X-K SSBs of the X SSBs within a second TXOP after the first TXOP, wherein each of the X SSBs is transmitted at a candidate SSB position corresponding to the SSB, and different SSBs correspond to different candidate SSB positions, wherein transmitting, by the network device, the remaining X-K SSBs of the X SSBs within the second TXOP after the first TXOP comprises: transmitting, by the network device, an SSB from a first SSB position capable of being used to transmit SSB within the second TXOP until the remaining X-K SSBs are transmitted, characterized in that, the network device repeatedly transmits the K SSBs respectively at K SSB positions corresponding to the K SSBs within the second TXOP. transmitting, by the network device, an SSB from a first SSB position capable of being used to transmit SSB within the second TXOP until the remaining X-K SSBs are transmitted, characterized in that, the network device repeatedly transmits the K SSBs respectively at K SSB positions corresponding to the K SSBs within the second TXOP.
An optical line terminal, comprising: means for acquiring device information of an optical network terminal that registers and gets online; wherein the device information comprises at least one of vendor information, device name information, and supported optical network terminal management and control interface, OMCI, protocol version information of the optical network terminal; means for matching an interoperability mode corresponding to the device information of the optical network terminal in an interoperability mode configuration table preset on the optical line terminal, means for determine whether the interoperability mode is the same as a current interoperability mode; and, in response to determining that the interoperability mode is different from the current interoperability mode, instructing the optical network terminal to be reset; means for switching the current interoperability mode to the interoperability mode, configuring and managing the optical network terminal according to the interoperability mode. means for acquiring device information of an optical network terminal that registers and gets online; wherein the device information comprises at least one of vendor information, device name information, and supported optical network terminal management and control interface, OMCI, protocol version information of the optical network terminal; means for matching an interoperability mode corresponding to the device information of the optical network terminal in an interoperability mode configuration table preset on the optical line terminal, means for determine whether the interoperability mode is the same as a current interoperability mode; and, in response to determining that the interoperability mode is different from the current interoperability mode, instructing the optical network terminal to be reset; means for switching the current interoperability mode to the interoperability mode, configuring and managing the optical network terminal according to the interoperability mode.
A semiconductor device comprising: a substrate made of silicon carbide and provided with a trench that has a wall surface having an off angle of not less than 50° and not more than 65° relative to a plane and that has an opening at a side of one main surface thereof; an oxide film formed on and in contact with said wall surface of said trench; and an electrode disposed on and in contact with said oxide film, said substrate including a source region having first conductivity type and formed to include said one main surface and said wall surface, a body region having second conductivity type and formed to include said wall surface and make contact with said source region, and a drift region having the first conductivity type and formed to include said wall surface and make contact with said body region so as to sandwich said body region between said source region and said drift region, wherein said source region and said body region are obtained by ion implantation, characterized in that said body region has a region that is sandwiched between said source region and said drift region and that has a thickness of 1 μm or smaller in a direction perpendicular to said one main surface, and said body region has an impurity concentration not smaller than 3 × 10 17 cm -3 and not greater than 2 × 10 18 cm -3. a substrate made of silicon carbide and provided with a trench that has a wall surface having an off angle of not less than 50° and not more than 65° relative to a plane and that has an opening at a side of one main surface thereof; an oxide film formed on and in contact with said wall surface of said trench; and an electrode disposed on and in contact with said oxide film, said substrate including a source region having first conductivity type and formed to include said one main surface and said wall surface, a body region having second conductivity type and formed to include said wall surface and make contact with said source region, and a drift region having the first conductivity type and formed to include said wall surface and make contact with said body region so as to sandwich said body region between said source region and said drift region, wherein said source region and said body region are obtained by ion implantation, characterized in that said body region has a region that is sandwiched between said source region and said drift region and that has a thickness of 1 μm or smaller in a direction perpendicular to said one main surface, and said body region has an impurity concentration not smaller than 3 × 10 17 cm -3 and not greater than 2 × 10 18 cm -3.
An electrical distribution system for a nuclear power plant, comprising: at least one primary alternating current power source; a first plurality of alternating current loads of a plurality of nuclear reactor systems of the nuclear power plant, each of the first plurality of alternating current loads comprising a critical electrical load of the plurality of nuclear reactor systems that is configured to fail to a safety position based on a loss of electrical power from the primary alternating current power source; a first alternating current power bus that is electrically coupled to the at least one primary alternating current power source and the first plurality of alternating current loads, wherein the first alternating current power bus is selectively coupled to a direct current power bus via an inverter/static switch (ISS, 530b), the direct current power bus being electrically coupled to the primary alternating power source through a charger/converter, and further being electrically coupled to a first critical battery system that comprises one or more nonqualified battery sources; a second plurality of alternating current loads of the plurality of nuclear reactor systems, each of the second plurality of alternating current loads comprising a non-critical electrical load of the plurality of nuclear reactor systems; and a second alternating current power bus that is electrically coupled to the at least one primary alternating current power source, the second plurality of alternating current loads, and a non-critical battery system that comprises one or more qualified battery sources. at least one primary alternating current power source; a first plurality of alternating current loads of a plurality of nuclear reactor systems of the nuclear power plant, each of the first plurality of alternating current loads comprising a critical electrical load of the plurality of nuclear reactor systems that is configured to fail to a safety position based on a loss of electrical power from the primary alternating current power source; a first alternating current power bus that is electrically coupled to the at least one primary alternating current power source and the first plurality of alternating current loads, wherein the first alternating current power bus is selectively coupled to a direct current power bus via an inverter/static switch (ISS, 530b), the direct current power bus being electrically coupled to the primary alternating power source through a charger/converter, and further being electrically coupled to a first critical battery system that comprises one or more nonqualified battery sources; a second plurality of alternating current loads of the plurality of nuclear reactor systems, each of the second plurality of alternating current loads comprising a non-critical electrical load of the plurality of nuclear reactor systems; and a second alternating current power bus that is electrically coupled to the at least one primary alternating current power source, the second plurality of alternating current loads, and a non-critical battery system that comprises one or more qualified battery sources.
A small-diameter drill having a diameter of 3mm or less and an end that has undergone cross thinning, wherein in a front view, a flute portion cutting edge is curved in concave against a rotational direction with respect to an imaginary straight line that connects a radially outer end of the flute portion cutting edge and a radially outer end of a thinning portion cutting edge, characterised in that a degree of concavity (d) of the flute portion cutting edge with respect to the imaginary straight line is set in a range of 0.5 to 2% of a drill diameter, furthermore, in that a ratio B: A of a length B of the thinning portion cutting edge to a length A of the flute portion cutting edge is set to 0.6 to 0.9: 1, and in that in an axially perpendicular cross-sectional view, a curvature radius R1 of a heel-side flute surface of a flute is set to be smaller than a curvature radius R2 of a flute surface along the flute portion cutting edge.
A nutritional composition comprising a protein component, a digestible carbohydrate component and a lipid component, wherein said lipid component comprises 10 to 50 wt.% vegetable lipids based on dry weight of the nutritional composition and 1.0 to 20 wt.% phospholipids based on total lipid, and wherein said lipid component comprises lipid globules with a core comprising said vegetable lipids and a coating comprising said phospholipids, for use in increasing the amount of n3 fatty acids and/or decreasing the ratio n6/n3 in cellular membranes, in an infant, by administration of the nutritional composition at a daily dose of at least 80 ml to said infant.
A method for producing a flexible ultrasonic transducer assembly, the method comprising: providing a flexible ultrasonic transducer, including at least a top electrode adjacent to a flexible piezoelectric film; bonding said top electrode to an insulating layer, the insulating layer having a shape and size to substantially surround a section of a component to be monitored; providing insulated electrical connection from the top electrode to an electronic control; providing a permanent or semi-permanent clamp adapted to apply at least a 0.2 MPa compressive pressure on a region of the component aligned with the top electrode; preparing a part of a surface of the section of the component; applying a couplant to the part of the surface to provide intimate physical contact between the couplant and the surface; and mounting the previously assembled layers to the couplant to provide intimate physical contact between the couplant and the flexible ultrasonic transducer, wherein applying the couplant comprises applying a soft metal, such as aluminum, gold, tin, zinc or other alloys known to the art of soldering and brazing applied as a foil; and mounting the previously assembled layers comprises applying an initial compressive stress greater than 1 MPa to plastically deform the soft metal foil. providing a flexible ultrasonic transducer, including at least a top electrode adjacent to a flexible piezoelectric film; bonding said top electrode to an insulating layer, the insulating layer having a shape and size to substantially surround a section of a component to be monitored; providing insulated electrical connection from the top electrode to an electronic control; providing a permanent or semi-permanent clamp adapted to apply at least a 0.2 MPa compressive pressure on a region of the component aligned with the top electrode; preparing a part of a surface of the section of the component; applying a couplant to the part of the surface to provide intimate physical contact between the couplant and the surface; and mounting the previously assembled layers to the couplant to provide intimate physical contact between the couplant and the flexible ultrasonic transducer, wherein applying the couplant comprises applying a soft metal, such as aluminum, gold, tin, zinc or other alloys known to the art of soldering and brazing applied as a foil; and mounting the previously assembled layers comprises applying an initial compressive stress greater than 1 MPa to plastically deform the soft metal foil.
Method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress during hemodialysis treatment comprising the steps of purifying a sample of plasma or serum from said kidney patient from human PTH peptides oxidized at either methionine 8 or 18 or both or at tryptophan 23 by contacting said sample with an antibody which recognizes and specifically binds a three-dimensional epitope located between amino acids 3 to 34 of oxidized human PTH peptides but which antibody does not bind non-oxidized human PTH and fragments thereof; determining the amount of immunoreactive human PTH (iPTH) peptides in said sample by an immunoassay based on antibodies against human PTH and fragments thereof that contain at least the domains responsible for receptor binding and activation of the cAMP-cyclase located between amino acids 3 to 34 of the human PTH sequence; and obtaining a PTH status value (n-oxPTH value) for said kidney patient which includes the rate of immunoreactive human PTH (iPTH) peptides secreted by cells of the parathyroid gland into the circulation and the rate by which immunoreactive human PTH (iPTH) peptides are oxidized by the oxidative stress suffered by said patient; and comparing the PTH status value (n-oxPTH) with a reference value at which the morbidity and all-cause mortality is low to determine the need of a medication with respect to a regulation of the PTH status value or for supplementation of the patient with human parathyroid hormone or active fragments thereof or both. purifying a sample of plasma or serum from said kidney patient from human PTH peptides oxidized at either methionine 8 or 18 or both or at tryptophan 23 by contacting said sample with an antibody which recognizes and specifically binds a three-dimensional epitope located between amino acids 3 to 34 of oxidized human PTH peptides but which antibody does not bind non-oxidized human PTH and fragments thereof; determining the amount of immunoreactive human PTH (iPTH) peptides in said sample by an immunoassay based on antibodies against human PTH and fragments thereof that contain at least the domains responsible for receptor binding and activation of the cAMP-cyclase located between amino acids 3 to 34 of the human PTH sequence; and obtaining a PTH status value (n-oxPTH value) for said kidney patient which includes the rate of immunoreactive human PTH (iPTH) peptides secreted by cells of the parathyroid gland into the circulation and the rate by which immunoreactive human PTH (iPTH) peptides are oxidized by the oxidative stress suffered by said patient; and comparing the PTH status value (n-oxPTH) with a reference value at which the morbidity and all-cause mortality is low to determine the need of a medication with respect to a regulation of the PTH status value or for supplementation of the patient with human parathyroid hormone or active fragments thereof or both.
Computer-implemented, trained machine learning system, wherein the machine learning system is a deep neural network having a convolution layer, comprising at least one filter, wherein the machine learning system is configured to take an input variable as a basis for using the filter to determine an output variable, wherein the input variable comprises a chronological sequence of images, wherein the machine learning system is configured to apply the filter to a sequence of pixels that are all located at the same coordinates in the images or at the same coordinates in intermediate results of the machine learning system, respectively, characterized in that the filter coefficients of the filter are quantized with a maximum of 8 bits and in that the quantizations of the filter coefficients of the filter were obtained by taking said filter coefficients into account for training the machine learning system, and in that the filter is configured to omit individual pixels of the images or of the intermediate results when the filter is used. wherein the machine learning system is a deep neural network having a convolution layer, comprising at least one filter, wherein the machine learning system is configured to take an input variable as a basis for using the filter to determine an output variable, wherein the input variable comprises a chronological sequence of images, wherein the machine learning system is configured to apply the filter to a sequence of pixels that are all located at the same coordinates in the images or at the same coordinates in intermediate results of the machine learning system, respectively, characterized in that the filter coefficients of the filter are quantized with a maximum of 8 bits and in that the quantizations of the filter coefficients of the filter were obtained by taking said filter coefficients into account for training the machine learning system, and in that the filter is configured to omit individual pixels of the images or of the intermediate results when the filter is used.
A particle therapy device, comprising: a gantry configured to receive a stream of particles generated by a particle accelerator; a treatment nozzle coupled to the gantry and configured to emit the stream of particles as a beam at a plurality of iso-centers disposed in a target subject; and a control system communicatively coupled to the treatment nozzle and configured to automatically control an emission of the beam of particles to irradiate a plurality of beam fields corresponding to the plurality of iso-centers, wherein the control system provides a graphical user interface that is configured to allow a user to group a subset of beam fields of the plurality of beam fields, the subset of beam fields corresponding to the same iso-centers disposed in the target subject, and wherein the graphical user interface further allows the user to disassociate a beam field from the group, wherein the control system is further configured to control the emission of the beam of particles to irradiate beam fields comprising the grouped subset of beam fields in a contiguous beam application, and to irradiate the disassociated beam field separately. a gantry configured to receive a stream of particles generated by a particle accelerator; a treatment nozzle coupled to the gantry and configured to emit the stream of particles as a beam at a plurality of iso-centers disposed in a target subject; and a control system communicatively coupled to the treatment nozzle and configured to automatically control an emission of the beam of particles to irradiate a plurality of beam fields corresponding to the plurality of iso-centers, wherein the control system provides a graphical user interface that is configured to allow a user to group a subset of beam fields of the plurality of beam fields, the subset of beam fields corresponding to the same iso-centers disposed in the target subject, and wherein the graphical user interface further allows the user to disassociate a beam field from the group, wherein the control system is further configured to control the emission of the beam of particles to irradiate beam fields comprising the grouped subset of beam fields in a contiguous beam application, and to irradiate the disassociated beam field separately.
Composition comprising a therapeutically effective amount of sandalwood oil for use in treating or preventing a Clostridium infection in the digestive tract of a subject, wherein the subject has a Clostridium infection or is at risk of developing a Clostridium infection.
A method for assessing an increased risk for cardiovascular mortality in a diabetic subject, comprising: (a) determining in a blood sample from said subject (ii) the amount of a first marker alpha-Glutathione-S-Transferase, and (b) correlating that said subject is at increased risk for mortality when said amount is altered compared to a reference amount for the first marker. (a) determining in a blood sample from said subject (ii) the amount of a first marker alpha-Glutathione-S-Transferase, and (b) correlating that said subject is at increased risk for mortality when said amount is altered compared to a reference amount for the first marker.
A method of inducing tissue-specific differentiation, comprising: a) culturing target tissue-specific fibroblast cells on a surface to produce an extracellular matrix; b) removing the fibroblast cells from the extracellular matrix to produce a tissue-specific differentiation matrix; and c) contacting isolated stem cells with the tissue-specific differentiation matrix to induce the stem cells to differentiate into the target cell type; wherein the target tissue-specific fibroblast cells are from skin, adipose tissue, cardiac tissue, kidney tissue, muscle tissue, liver tissue, pancreas tissue, tissue of the endometrium of uterus, umbilical cord tissue-derived fibroblasts, or dental pulp cells. a) culturing target tissue-specific fibroblast cells on a surface to produce an extracellular matrix; b) removing the fibroblast cells from the extracellular matrix to produce a tissue-specific differentiation matrix; and c) contacting isolated stem cells with the tissue-specific differentiation matrix to induce the stem cells to differentiate into the target cell type;